top of page

Potentially Lifesaving
Monoclonal Antibodies

We are a life sciences company pioneering therapies for hematology/oncology and chronic inflammation. Our leading drug candidate, Lenzilumab (LENZ), is in a Phase 2/3 trial for Chronic Myelomonocytic Leukemia (CMML), with an initial response rate more than twice standard of care in early findings. Our vision is to save the lives of patients facing this devastating disease.

Cautionary Note Regarding Forward-Looking Statements All statements other than statements of historical facts contained in this presentation are forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment, and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct, and you should be aware that actual events or results may differ materially from those contained in the forward- looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and need for additional capital; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development, attainment of the requisite regulatory authorizations and approvals and launch of any new pharmaceutical product; the outcome of pending or future litigation or arbitration; and the various risks and uncertainties described in the "Risk Factors" sections of our latest annual and quarterly reports and other filings with the SEC. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not rely upon any forward-looking statements as predictions of future events. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof, to reflect new information or the occurrence of unanticipated events, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, in each case, except as required by law.

© copyright 2024, Taran Therapeutics LLC, all rights reserved

Screen Shot 2024-04-06 at 2.11.01 PM.png
bottom of page